Online citations, reference lists, and bibliographies.
← Back to Search

Molecular Modeling Study For Inhibition Mechanism Of Human Chymase And Its Application In Inhibitor Design

M. Arooj, Songmi Kim, S. Sakkiah, G. P. Cao, Yuno Lee, K. Lee
Published 2013 · Chemistry, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Human chymase catalyzes the hydrolysis of peptide bonds. Three chymase inhibitors with very similar chemical structures but highly different inhibitory profiles towards the hydrolase function of chymase were selected with the aim of elucidating the origin of disparities in their biological activities. As a substrate (angiotensin-I) bound crystal structure is not available, molecular docking was performed to dock the substrate into the active site. Molecular dynamics simulations of chymase complexes with inhibitors and substrate were performed to calculate the binding orientation of inhibitors and substrate as well as to characterize conformational changes in the active site. The results elucidate details of the 3D chymase structure as well as the importance of K40 in hydrolase function. Binding mode analysis showed that substitution of a heavier Cl atom at the phenyl ring of most active inhibitor produced a great deal of variation in its orientation causing the phosphinate group to interact strongly with residue K40. Dynamics simulations revealed the conformational variation in region of V36-F41upon substrate and inhibitor binding induced a shift in the location of K40 thus changing its interactions with them. Chymase complexes with the most activecompound and substrate were used for development of a hybrid pharmacophore model which was applied in databases screening. Finally, hits which bound well at the active site, exhibited key interactions and favorable electronic properties were identified as possible inhibitors for chymase. This study not only elucidates inhibitory mechanism of chymase inhibitors but also provides key structural insights which will aid in the rational design of novel potent inhibitors of the enzyme. In general, the strategy applied in the current study could be a promising computational approach and may be generally applicable to drug design for other enzymes.
This paper references
10.1016/s0169-409x(96)00423-1
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.
C. Lipinski (2001)
10.1021/BI971403N
Crystal structure of phenylmethanesulfonyl fluoride-treated human chymase at 1.9 A.
M. Mcgrath (1997)
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced drug delivery reviews
Ca Lipinski (2012)
10.1006/BBRC.1997.7875
Three-dimensional molecular modeling explains why catalytic function for angiotensin-I is different between human and rat chymases.
D. Yamamoto (1998)
10.3390/ijms12129236
3D QSAR Pharmacophore Modeling, in Silico Screening, and Density Functional Theory (DFT) Approaches for Identification of Human Chymase Inhibitors
M. Arooj (2011)
Novel, Potent Dual Inhibitor of the Leukocyte Proteases Cathepsin G and Chymase MOLECULAR MECHANISMS AND ANTI-INFLAMMATORY ACTIVITY IN VIVO
L De Garavilla (2005)
10.1073/PNAS.92.15.6738
Inhibitors of human heart chymase based on a peptide library.
M. Bastos (1995)
10.1007/s10103-008-0558-y
Possible roles of mast cell-derived chymase for skin rejuvenation
N. Amano (2008)
10.1016/S0167-4838(02)00224-8
Lys40 but not Arg143 influences selectivity of angiotensin conversion by human α-chymase
D. Muilenburg (2002)
10.1016/S0960-894X(00)00488-1
Synthesis and structure-activity relationships of a new class of 1-oxacephem-based human chymase inhibitors.
Y. Aoyama (2000)
10.2174/1570180053398433
Inhibition of Transforming Growth Factor- βActivation is a Novel Effect of Chymase Inactivation
S. Miyazaki (2005)
10.1182/blood-2010-01-257287
Mast cell proteases: multifaceted regulators of inflammatory disease.
G. Pejler (2010)
10.1093/EURHEARTJ/EHM003
Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study.
D. Kelly (2007)
10.1016/j.bcp.2010.06.014
Potency variation of small-molecule chymase inhibitors across species.
J. Kervinen (2010)
10.1074/JBC.M501302200
A Novel, Potent Dual Inhibitor of the Leukocyte Proteases Cathepsin G and Chymase
L. de Garavilla (2005)
10.1002/jcc.20634
A semiempirical free energy force field with charge‐based desolvation
R. Huey (2007)
Lys, sup.40,/sup. but not Arg, sup.143,/sup. influences selectivity of angiotensin conversion by human a-chymase
D J Muilenburg (2002)
10.1093/eurheartj/ehq030
Novel therapeutic concepts: the epidemic of cardiovascular disease in the developing world: global implications.
B. Gersh (2010)
10.1002/BIP.360340114
Solitary wave dynamics as a mechanism for explaining the internal motion during microtubule growth
K. Chou (1994)
10.1152/ajprenal.00641.2009
Chymase: the other ACE?
J. Lorenz (2010)
3D QSAR Pharmacophore Modeling
M Arooj (2011)
Insight into the molecular switch mechanism of human Rab 5 a from molecular dynamics simulations
JF Wang (2009)
Insight into the molecular switch mechanism of human Rab5a from molecular dynamics simulations. Biochemical and biophysical research communications
JF Wang (2009)
Threedimensional molecular modeling explains why catalytic function for angiotensin- I is different between human and rat chymases. Biochemical and biophysical research communications 242
D Yamamoto (1998)
10.1097/GIM.0b013e3181804b9c
Genotype-phenotype associations between chymase and angiotensin—converting enzyme gene polymorphisms in chronic systolic heart failure patients
R. Amir (2008)
10.1016/j.bbrc.2009.10.014
Insight into the molecular switch mechanism of human Rab5a from molecular dynamics simulations.
J. Wang (2009)
10.1038/nsmb1137
A peptide motif in Raver1 mediates splicing repression by interaction with the PTB RRM2 domain
A. Rideau (2006)
10.1016/S0960-894X(99)00659-9
Structure-activity relationship studies of chloromethyl ketone derivatives for selective human chymase inhibitors.
Y. Hayashi (2000)
10.1016/J.BMCL.2003.08.040
Structure-activity relationship of benzo[b]thiophene-2-sulfonamide derivatives as novel human chymase inhibitors.
Hidekazu Masaki (2003)
10.1021/JM0700619
Discovery of potent, selective, orally active, nonpeptide inhibitors of human mast cell chymase.
M. N. Greco (2007)
10.1016/S0960-894X(01)00265-7
Total synthesis of human chymase inhibitor methyllinderone and structure--activity relationships of its derivatives.
Y. Aoyama (2001)
10.1016/S0960-894X(02)00853-3
Identification of a stable chymase inhibitor using a pharmacophore-Based database search.
Y. Koide (2003)
10.1021/ct700301q
GROMACS 4:  Algorithms for Highly Efficient, Load-Balanced, and Scalable Molecular Simulation.
B. Hess (2008)
10.1021/JM061277Y
Diverse, high-quality test set for the validation of protein-ligand docking performance.
M. J. Hartshorn (2007)
10.1002/BIP.360271109
Collective motion in DNA and its role in drug intercalation
K. Chou (1988)
10.1007/s00395-010-0093-4
Impact of acute myocardial ischemia reperfusion on the tissue and blood-borne renin–angiotensin system
Shizu Oyamada (2010)
10.1111/cbdd.12006
Computational Studies of Novel Chymase Inhibitors Against Cardiovascular and Allergic Diseases: Mechanism and Inhibition
M. Arooj (2012)
10.1002/jcc.20291
GROMACS: Fast, flexible, and free
D. Spoel (2005)
10.1097/01.ASN.0000071512.93927.4E
Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease.
X. Huang (2003)
10.4049/jimmunol.177.12.8315
Human Mast Cell Chymase Cleaves Pro-IL-18 and Generates a Novel and Biologically Active IL-18 Fragment1
Y. Omoto (2006)
10.1016/S0167-4838(00)00076-5
Angiotensin II generation by mast cell α- and β-chymases
G. Caughey (2000)



This paper is referenced by
Planejamento in silico de novos inibidores da enzima Guanina Fosforibosil Transferase de Giardia lamblia como possíveis candidatos a fármacos antiparasitários.
Gustavo Machado das Neves (2015)
10.1002/minf.201800037
COX Inhibition Profiles and Molecular Docking Studies of the Lignan Hinokinin and Some Synthetic Derivatives
Alexandre Borges (2018)
10.1016/j.jmgm.2019.03.011
Structure-based virtual screening for novel chymase inhibitors by in silico fragment mapping.
Shin-ichiro Ozawa (2019)
10.1021/ED500195D
Using Free Computational Resources to Illustrate the Drug Design Process in an Undergraduate Medicinal Chemistry Course.
R. P. Rodrigues (2015)
10.1007/978-3-030-31403-3_11
Design of Inhibitors of the Human Fibroblast Activation Protein α as a Strategy to Hinder Metastasis and Angiogenesis
D. Kawano (2020)
10.1007/s11030-017-9745-8
Identification of a novel putative inhibitor of the Plasmodium falciparum purine nucleoside phosphorylase: exploring the purine salvage pathway to design new antimalarial drugs
L. P. Kagami (2017)
10.1007/s00726-020-02897-2
Physicochemical stability study of protein-benzoic acid complexes using molecular dynamics simulations.
M. Arooj (2020)
10.3390/biom9010005
Searching for Chymase Inhibitors among Chamomile Compounds Using a Computational-Based Approach
Amit Dubey (2018)
10.1016/j.pep.2014.08.005
Expression of recombinant human mast cell chymase with Asn-linked glycans in glycoengineered Pichia pastoris.
Eliot T Smith (2014)
10.1016/j.gene.2017.01.030
Dissecting the role of mutations in chymase inhibition: Free energy and decomposition analysis.
S. Verma (2017)
Semantic Scholar Logo Some data provided by SemanticScholar